Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2006
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
Plasma-Lyte 148 and dextrose (Injection, Solution)
|
dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit. All injections in
Viaflex' plastic containers are intended for intravenous administration
using sterile equipment. As reported in the
literature, the dosage and constant infusion rate of intravenous
dextrose must be selected with caution in pediatric patients,
particularly neonates and low weight infants, because of the increased
risk of hyperglycemia/hypoglycemia. Additives may be
incompatible. Complete information is not available. Those additives
known to be incompatible should not be used. Consult with pharmacist, if
available. If, in the informed judgment of the physician, it is deemed
advisable to introduce additives, use aseptic technique. Mix thoroughly
when additives have been introduced. Do not store solutions containing
additives.
|
dailymed-instance:descripti... |
Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container
for intravenous administration. Each 100 mL contains 5 g Dextrose
Hydrous, USP*, 526 mg Sodium Chloride, USP (NaCl); 502 mg Sodium
Gluconate (CHNaO); 368 mg Sodium
Acetate Trihydrate, USP
(CHNaO���3HO), 37 mg
Potassium Chloride, USP (KCl); and 30 mg Magnesium Chloride, USP
(MgCl���6HO). It contains no antimicrobial
agents. The pH is 5.0 (4.0 to 6.5). The pH is adjusted with hydrochloric
acid. Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) administered intravenously has value as a source of water,
electrolytes, and calories. One liter has an ionic concentration of 140
mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq
acetate and 23 mEq gluconate. The osmolarity is 547 mOsmol/L (calc).
Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (���600
mOsmol/L) may cause vein damage. The caloric content is 190 kcal/L. The Viaflex'
plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146' Plastic). The amount of water that can permeate from
inside the container into the overwrap is insufficient to affect the
solution significantly. Solutions in contact with the plastic container
may leach out certain chemical components from the plastic in very small
amounts; however, biological testing was supportive of the safety of the
plastic container materials.
|
dailymed-instance:clinicalP... |
Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) has value as a source of water, electrolytes, and calories. It is capable of inducing diuresis depending on the clinical condition
of the patient. Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) produces a metabolic alkalinizing effect. Acetate and
gluconate ions are metabolized ultimately to carbon dioxide and water,
which requires the consumption of hydrogen cations.
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
Solutions containing dextrose may be contraindicated in patients with known
allergy to corn or corn products.
|
dailymed-instance:supply |
Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) in Viaflex' plastic containers is available as shown below: Exposure of
pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature (25��C); brief exposure up to 40��C does not adversely affect the
product.
|
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... | |
dailymed-instance:genericMe... |
Sodium chloride, potassium chloride, calcium chloride, sodium gluconate, sodium acetate and dextrose
|
dailymed-instance:fullName |
Plasma-Lyte 148 and dextrose (Injection, Solution)
|
dailymed-instance:adverseRe... |
Reactions which may
occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation and
hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures, and save the
remainder of the fluid for examination if deemed necessary.
|
dailymed-instance:warning |
Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) should be used with great care, if at all, in patients with
congestive heart failure, severe renal insufficiency and in clinical
states in which there exists edema with sodium retention. Plasma-Lyte' 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) should be used with great care, if at all, in patients with
hyperkalemia, severe renal failure and in conditions in which potassium
retention is present. Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) should be used with great care in patients with metabolic
or respiratory alkalosis. The administration of acetate or gluconate
ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as
severe hepatic insufficiency. The intravenous
administration of Plasma-Lyte' 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fluid and/or
solute overloading resulting in dilution of serum electrolyte
concentrations, overhydration, congested states, or pulmonary edema. The
risk of dilutional states is inversely proportional to the electrolyte
concentrations of the injection. The risk of solute overload causing
congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injection. In patients with
diminished renal function, administration of Plasma-Lyte' 148 and 5%
Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type
1, USP) may result in sodium or potassium retention.
|
dailymed-instance:indicatio... |
Plasma-Lyte' 148
and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 1, USP) is indicated as a source of water, electrolytes, and
calories, or as an alkalinizing agent.
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
Plasma-Lyte 148 and dextrose
|